abrdn Life Sciences Investors
CIK: 0000884121
HQL
Equity
Holdings
From latest SEC N-PORT filing · US-listed stocks only
| # | Security Name | CUSIP | Asset Type | Weight % | Value ($M) | Quantity |
|---|---|---|---|---|---|---|
| 1 | JBIO Jade Biosciences Inc Since 2026-07-07 | 008064206 | Equity (Common) |
0.70%
|
$3.90 | 277,555 |
| 2 | AGMB AgomAb Therapeutics NV Since 2026-07-07 | 00860C102 | Equity (Common) |
0.27%
|
$1.49 | 141,787 |
| 3 | ALLO Allogene Therapeutics Inc Since 2026-07-07 | 019770106 | Equity (Common) |
0.64%
|
$3.57 | 1,462,219 |
| 4 | ALNY Alnylam Pharmaceuticals Inc Since 2026-07-07 | 02043Q107 | Equity (Common) |
1.78%
|
$10.00 | 30,216 |
| 5 | AMGN Amgen Inc Since 2026-07-07 | 031162100 | Equity (Common) |
1.17%
|
$6.55 | 18,629 |
| 6 | APGE Apogee Therapeutics Inc Since 2026-07-07 | 03770N101 | Equity (Common) |
1.15%
|
$6.47 | 76,841 |
| 7 | RCUS Arcus Biosciences Inc Since 2026-07-07 | 03969F109 | Equity (Common) |
0.54%
|
$3.03 | 140,418 |
| 8 | ARQT Arcutis Biotherapeutics Inc Since 2026-07-07 | 03969K108 | Equity (Common) |
0.61%
|
$3.40 | 144,311 |
| 9 | ARWR Arrowhead Pharmaceuticals Inc Since 2026-07-07 | 04280A100 | Equity (Common) |
1.60%
|
$8.98 | 143,265 |
| 10 | ASND Ascendis Pharma A/S Since 2026-07-07 | 04351P101 | Equity (Common) |
0.47%
|
$2.64 | 11,544 |
| 11 | AVTX Avalo Therapeutics Inc Since 2026-07-07 | 05338F306 | Equity (Common) |
0.46%
|
$2.56 | 171,679 |
| 12 | AXSM Axsome Therapeutics Inc Since 2026-07-07 | 05464T104 | Equity (Common) |
2.22%
|
$12.46 | 73,746 |
| 13 | BCRX BioCryst Pharmaceuticals Inc Since 2026-07-07 | 09058V103 | Equity (Common) |
1.69%
|
$9.48 | 996,017 |
| 14 | CRBU Caribou Biosciences Inc Since 2026-07-07 | 142038108 | Equity (Common) |
0.41%
|
$2.30 | 1,212,541 |
| 15 | CDXS Codexis Inc Since 2026-07-07 | 192005106 | Equity (Common) |
0.90%
|
$5.04 | 3,090,272 |
| 16 | COGT Cogent Biosciences Inc Since 2026-07-07 | 19240Q201 | Equity (Common) |
0.67%
|
$3.77 | 97,873 |
| 17 | CRBP Corbus Pharmaceuticals Holdings Inc Since 2026-07-07 | 21833P301 | Equity (Common) |
0.91%
|
$5.11 | 543,719 |
| 18 | CRNX Crinetics Pharmaceuticals Inc Since 2026-07-07 | 22663K107 | Equity (Common) |
2.02%
|
$11.34 | 312,153 |
| 19 | DNLI Denali Therapeutics Inc Since 2026-07-07 | 24823R105 | Equity (Common) |
2.28%
|
$12.76 | 664,716 |
| 20 | IRON Disc Medicine Inc Since 2026-07-07 | 254604101 | Equity (Common) |
1.13%
|
$6.35 | 99,339 |
| 21 | DYN Dyne Therapeutics Inc Since 2026-07-07 | 26818M108 | Equity (Common) |
2.47%
|
$13.85 | 763,959 |
| 22 | EWTX Edgewise Therapeutics Inc Since 2026-07-07 | 28036F105 | Equity (Common) |
1.98%
|
$11.12 | 353,076 |
| 23 | EQ Equillium Inc Since 2026-07-07 | 29446K106 | Equity (Common) |
1.20%
|
$6.71 | 3,352,837 |
| 24 | EYPT EyePoint Inc Since 2026-07-07 | 30233G209 | Equity (Common) |
1.42%
|
$7.94 | 616,005 |
| 25 | FULC Fulcrum Therapeutics Inc Since 2026-07-07 | 359616109 | Equity (Common) |
2.08%
|
$11.65 | 1,518,506 |
| 26 | GRAL GRAIL Inc Since 2026-07-07 | 384747101 | Equity (Common) |
0.68%
|
$3.80 | 73,603 |
| 27 | GH Guardant Health Inc Since 2026-07-07 | 40131M109 | Equity (Common) |
0.66%
|
$3.71 | 40,219 |
| 28 | IDYA Ideaya Biosciences Inc Since 2026-07-07 | 45166A102 | Equity (Common) |
1.25%
|
$7.02 | 210,611 |
| 29 | IMVT Immunovant Inc Since 2026-07-07 | 45258J102 | Equity (Common) |
1.96%
|
$10.97 | 441,498 |
| 30 | IMUX Immunic Inc Since 2026-07-07 | 4525EP101 | Equity (Common) |
0.60%
|
$3.36 | 3,028,916 |
| 31 | IONS Ionis Pharmaceuticals Inc Since 2026-07-07 | 462222100 | Equity (Common) |
0.47%
|
$2.62 | 34,943 |
| 32 | IOVA Iovance Biotherapeutics Inc Since 2026-07-07 | 462260100 | Equity (Common) |
0.10%
|
$0.54 | 155,000 |
| 33 | KRYS Krystal Biotech Inc Since 2026-07-07 | 501147102 | Equity (Common) |
0.53%
|
$2.95 | 11,430 |
| 34 | LENZ LENZ Therapeutics Inc Since 2026-07-07 | 52635N103 | Equity (Common) |
0.61%
|
$3.40 | 371,775 |
| 35 | LXEO Lexeo Therapeutics Inc Since 2026-07-07 | 52886X107 | Equity (Common) |
0.25%
|
$1.41 | 245,904 |
| 36 | MAZE Maze Therapeutics Inc Since 2026-07-07 | 578784100 | Equity (Common) |
0.29%
|
$1.63 | 54,644 |
| 37 | NBIX Neurocrine Biosciences Inc Since 2026-07-07 | 64125C109 | Equity (Common) |
0.38%
|
$2.14 | 16,247 |
| 38 | NUVL Nuvalent Inc Since 2026-07-07 | 670703107 | Equity (Common) |
1.02%
|
$5.71 | 55,694 |
| 39 | OCUL Ocular Therapeutix Inc Since 2026-07-07 | 67576A100 | Equity (Common) |
0.27%
|
$1.54 | 182,062 |
| 40 | ORKA Oruka Therapeutics Inc Since 2026-07-07 | 687604108 | Equity (Common) |
0.66%
|
$3.71 | 75,680 |
| 41 | PALI Palisade Bio Inc Since 2026-07-07 | 696389402 | Equity (Common) |
0.21%
|
$1.16 | 662,900 |
| 42 | PVLA Palvella Therapeutics Inc Since 2026-07-07 | 697947109 | Equity (Common) |
0.59%
|
$3.28 | 26,322 |
| 43 | PSNL Personalis Inc Since 2026-07-07 | 71535D106 | Equity (Common) |
1.63%
|
$9.11 | 1,430,790 |
| 44 | PRAX Praxis Precision Medicines Inc Since 2026-07-07 | 74006W207 | Equity (Common) |
1.62%
|
$9.10 | 28,244 |
| 45 | DTIL Precision BioSciences Inc Since 2026-07-07 | 74019P207 | Equity (Common) |
1.07%
|
$5.97 | 1,085,970 |
| 46 | REGN Regeneron Pharmaceuticals Inc Since 2026-07-07 | 75886F107 | Equity (Common) |
1.71%
|
$9.58 | 12,398 |
| 47 | RVMD Revolution Medicines Inc Since 2026-07-07 | 76155X100 | Equity (Common) |
0.64%
|
$3.57 | 36,678 |
| 48 | RYTM Rhythm Pharmaceuticals Inc Since 2026-07-07 | 76243J105 | Equity (Common) |
0.50%
|
$2.82 | 32,407 |
| 49 | RCKT Rocket Pharmaceuticals Inc Since 2026-07-07 | 77313F106 | Equity (Common) |
0.42%
|
$2.38 | 664,821 |
| 50 | SRPT Sarepta Therapeutics Inc Since 2026-07-07 | 803607100 | Equity (Common) |
1.62%
|
$9.06 | 416,313 |
| 51 | WGS GeneDx Holdings Corp Since 2026-07-07 | 81663L200 | Equity (Common) |
0.32%
|
$1.77 | 27,631 |
| 52 | STTK Shattuck Labs Inc Since 2026-07-07 | 82024L103 | Equity (Common) |
1.33%
|
$7.45 | 1,159,321 |
| 53 | SPRY ARS Pharmaceuticals Inc Since 2026-07-07 | 82835W108 | Equity (Common) |
0.91%
|
$5.13 | 638,505 |
| 54 | SION Sionna Therapeutics Inc Since 2026-07-07 | 829401108 | Equity (Common) |
1.20%
|
$6.74 | 168,051 |
| 55 | SLNO Soleno Therapeutics Inc Since 2026-07-07 | 834203309 | Equity (Common) |
0.58%
|
$3.26 | 97,455 |
| 56 | SGP SpyGlass Pharma Inc Since 2026-07-07 | 85220G109 | Equity (Common) |
0.16%
|
$0.92 | 35,455 |
| 57 | SMMT Summit Therapeutics Inc Since 2026-07-07 | 86627T108 | Equity (Common) |
0.81%
|
$4.52 | 238,231 |
| 58 | SNDX Syndax Pharmaceuticals Inc Since 2026-07-07 | 87164F105 | Equity (Common) |
1.20%
|
$6.70 | 286,969 |
| 59 | TSHA Taysha Gene Therapies Inc Since 2026-07-07 | 877619106 | Equity (Common) |
0.81%
|
$4.56 | 1,021,063 |
| 60 | TECX Tectonic Therapeutic Inc Since 2026-07-07 | 878972108 | Equity (Common) |
2.04%
|
$11.46 | 370,884 |
| 61 | TEM Tempus AI Inc Since 2026-07-07 | 88023B103 | Equity (Common) |
0.51%
|
$2.84 | 62,796 |
| 62 | TVTX Travere Therapeutics Inc Since 2026-07-07 | 89422G107 | Equity (Common) |
1.08%
|
$6.06 | 203,913 |
| 63 | TCRX TScan Therapeutics Inc Since 2026-07-07 | 89854M101 | Equity (Common) |
0.15%
|
$0.84 | 836,783 |
| 64 | PCVX Vaxcyte Inc Since 2026-07-07 | 92243G108 | Equity (Common) |
2.97%
|
$16.67 | 286,930 |
| 65 | IMUX IMMUNIC INC. Since 2026-07-07 | — | Derivative |
0.46%
|
$2.57 | 2,311,826 |
| 66 | IMUX IMMUNIC INC. Since 2026-07-07 | — | Derivative |
0.30%
|
$1.68 | 2,311,826 |
| 67 | XENE Xenon Pharmaceuticals Inc Since 2026-07-07 | 98420N105 | Equity (Common) |
2.10%
|
$11.79 | 202,664 |
| 68 | EVMN EVOMMUNE Since 2026-07-07 | — | Equity (Common) |
0.24%
|
$1.34 | 58,305 |
| 69 | IMUX IMMUNIC Since 2026-07-07 | — | Derivative |
0.88%
|
$4.93 | 4,444,604 |
| 70 | IMUX IMMUNIC Since 2026-07-07 | — | Derivative |
0.38%
|
$2.16 | 4,444,604 |
| 71 | DTIL PRECISION BIOSCIENCES Since 2026-07-07 | — | Derivative |
0.18%
|
$1.03 | 336,267 |
| 72 | BHVN Biohaven Ltd Since 2026-07-07 | — | Equity (Common) |
1.16%
|
$6.53 | 771,452 |
| 73 | JAZZ Jazz Pharmaceuticals PLC Since 2026-07-07 | — | Equity (Common) |
0.60%
|
$3.38 | 17,872 |
| 74 | OCS Oculis Holding AG Since 2026-07-07 | — | Equity (Common) |
1.20%
|
$6.75 | 253,740 |
| 75 | WVE WaVe Life Sciences Ltd Since 2026-07-07 | — | Equity (Common) |
0.19%
|
$1.09 | 150,000 |
Frequently Asked Questions — abrdn Life Sciences Investors
What type of mutual fund is abrdn Life Sciences Investors?
abrdn Life Sciences Investors is a SEC-registered Equity fund, with $561M in assets under management.
Equity funds invest primarily in a diversified portfolio of stocks and equities, aiming for long-term capital appreciation. They carry higher market risk than bond or money market funds but historically offer stronger long-term returns. Equity mutual funds can be further classified as large-cap, mid-cap, small-cap, growth, value, or sector-specific depending on their investment mandate.
As of its latest SEC N-PORT filing, abrdn Life Sciences Investors holds 75 portfolio positions, all detailed in the holdings table on this page.
What are abrdn Life Sciences Investors's assets under management (AUM)?
abrdn Life Sciences Investors has $561M in assets under management (AUM) according to its most recent SEC N-PORT filing on StockSifting.
AUM represents the total market value of all securities and other assets held by the fund as of the report date. A larger AUM generally signals a more established fund with greater institutional adoption, more trading liquidity, and potentially lower per-unit operational costs due to economies of scale.
AUM changes daily as market prices fluctuate and as investors purchase or redeem fund shares — the figure shown here reflects the most recently available N-PORT disclosure, not the current real-time value. For the live figure, consult the fund's official website or its latest SEC EDGAR filing.
What are abrdn Life Sciences Investors's top holdings?
According to abrdn Life Sciences Investors's most recent SEC N-PORT filing, the fund's largest holdings by portfolio weight include
Jade Biosciences Inc,
AgomAb Therapeutics NV,
Allogene Therapeutics Inc
, among others.
The complete list of all 75 holdings — including CUSIP, asset type, portfolio weight percentage, dollar value, and share quantity — is available in the holdings table above.
Holdings data is sourced directly from SEC EDGAR N-PORT filings and reflects the fund's positions as of the report date shown at the top of this page. Due to the 60-day SEC disclosure lag, these positions may differ from the fund's current portfolio. For the latest holdings before public release, refer to SEC EDGAR directly.
What is abrdn Life Sciences Investors's expense ratio?
Expense ratio data for abrdn Life Sciences Investors is not currently available in StockSifting's database.
The expense ratio is the annual fee charged by a mutual fund as a percentage of your investment, covering management fees and operational costs. It is one of the most important factors affecting net long-term returns — lower expense ratios allow more of a fund's gross performance to flow through to investors.
For the most accurate and current expense ratio, refer to the fund's official prospectus or its SEC EDGAR filings. You can also contact us if you believe this data should be present.
Where can I find abrdn Life Sciences Investors's SEC filings?
abrdn Life Sciences Investors is required to file monthly portfolio reports (Form N-PORT) with the U.S. Securities and Exchange Commission (SEC). Its SEC Central Index Key (CIK) is 0000884121.
You can access all of abrdn Life Sciences Investors's SEC filings — including N-PORT holdings disclosures, annual reports (Form N-CEN), and registration statements — directly on
SEC EDGAR (CIK: 0000884121).
N-PORT filings disclose the fund's complete portfolio holdings, fair value measurements, and certain risk metrics as of each filing period end date. StockSifting automatically parses these filings to populate the holdings table, AUM figures, and expense ratio displayed on this page, making the raw EDGAR data accessible without needing to download and parse XML files manually.
How current is abrdn Life Sciences Investors's holdings data on StockSifting?
Holdings data for abrdn Life Sciences Investors on StockSifting is sourced from its most recent SEC EDGAR N-PORT filing.
Under SEC rules, registered investment companies must file N-PORT reports monthly, but these are made publicly available approximately 60 days after the reporting period end date. This means the holdings shown on this page reflect the fund's portfolio from roughly two months prior — not today's exact positions.
The Report date displayed at the top of this page indicates exactly when the underlying data was current. If the fund has made significant portfolio changes since that date — responding to market events, earnings releases, or macro shifts — those changes will not be reflected here until the next N-PORT filing is released.
For the most up-to-date holdings before the public disclosure window, refer to the fund's official website or SEC EDGAR directly. StockSifting is best used for fundamental research and historical portfolio analysis, not real-time trading decisions.